Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : INCY crawled date : 2021 - 07 - 16 save search
Oncology (Cancer) / Hematologic Malignancies Approval Notifications
Published: 2021-07-16 (Crawled : 19:11) - fda.gov
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
| Email alert
Add to watchlist
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
| Email alert
Add to watchlist
CLVS | $0.0812 -3.94%
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
| Email alert
Add to watchlist
KPTI | $1.085 -3.98% -4.15% 1.6M
|
Health Technology
| Email alert
Add to watchlist
ADCT | $4.97 6.2% 2.21% 400K
|
Health Technology
| Email alert
Add to watchlist
YMAB | $15.37 1.39% 1.37% 510K
|
Health Technology
| Email alert
Add to watchlist
BPMC | $92.32 1.89% 1.85% 780K
|
Health Technology
| Email alert
Add to watchlist
EPZM | $1.47 -1.34% 0.0%
|
Health Technology
| Email alert
Add to watchlist
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
| Email alert
Add to watchlist
AVEO | $15.0 0.0% 0
|
Health Technology
| Email alert
Add to watchlist
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
| Email alert
Add to watchlist
cancer approval
Lilly and Incyte provide update on supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis
Published: 2021-07-16 (Crawled : 14:00) - prnewswire.com
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: 0.3%
H: 0.44%
C: -2.37%
new drug baricitinib treatment dermatitis drug atopic dermatitis
Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI319 (Anti-PD-1/CD137 Bispecific Antibody) in Patients with Advanced Malignant Tumors
Published: 2021-07-16 (Crawled : 01:00) - prnewswire.com
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: 0.3%
H: 0.44%
C: -2.37%
phase 1 antibody phase 2
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 870K
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.